سعر سيفترياكسون-إيفا 500 مجم فيال وريد 2026

Ceftriaxone-eva 500 mg i.v. vial: Ceftriaxone (Eva Pharma).

• Parenteral third-generation cephalosporin for susceptible infections including lower respiratory tract, skin/skin structure, urinary tract, uncomplicated gonorrhea, pelvic inflammatory disease, bacterial septicemia, bone and joint, intra-abdominal, meningitis, and surgical prophylaxis as labeled (US ceftriaxone injectable labeling).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Local reactions, gastrointestinal symptoms, hypersensitivity, and hematologic/hepatic lab changes reported; see full US label for frequencies.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Contraindicated with known hypersensitivity to ceftriaxone, its excipients, or other cephalosporins; do not use in hyperbilirubinemic neonates or with concurrent IV calcium in neonates as labeled (US labels).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Serious hypersensitivity reactions possible; Clostridioides difficile–associated diarrhea reported with nearly all antibacterials; monitor and manage per label (US injectable cephalosporin labeling).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Calcium-containing IV solutionsMajorDo not mix/co-administer IV ceftriaxone with calcium-containing IV solutions in neonates; precipitation risk (US labels).DailyMed (U.S. National Library of Medicine)

• Animal studies without clear teratogenicity at multiples of human dose; limited adequate controlled human data — use only if clearly needed (US labels).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Low concentrations excreted in human milk; caution in nursing women (US labels).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Ceftriaxone: Long-acting third-generation cephalosporin inhibiting cell-wall synthesis via PBP binding; once-daily dosing common.